African trypanosomiasis, widely known as human African sleeping sickness, is a devastating vector-borne parasitic disease that has shaped the demographic, economic, and epidemiological landscapes of sub-Saharan Africa for centuries. Transmitted through the bite of infected tsetse flies, the disease invariably progresses from an initial systemic infection to severe neuroinflammation, profound disruptions of the sleep-wake cycle, coma, and death if left untreated. Understanding its pathogenesis, clinical trajectory, and evolving diagnostic and pharmacological landscapes provides crucial insights into host-parasite dynamics and modern neglected tropical disease eradication strategies.
African Trypanosomiasis
1. Concise Definition
African trypanosomiasis is a vector-borne protozoan infection caused by microscopic flagellate parasites belonging to the genus Trypanosoma and transmitted to mammalian hosts through the bite of infected tsetse flies (genus Glossina). In humans, the condition is specifically designated as Human African Trypanosomiasis (HAT) and is categorized into two geographically and clinically distinct entities: a chronic form prevalent in Western and Central Africa caused by Trypanosoma brucei gambiense, and an acute, fulminant form found predominantly in Eastern and Southern Africa caused by Trypanosoma brucei rhodesiense.
Pathologically, the infection advances through two distinct evolutionary stages. The first, or hemolymphatic stage, is characterized by the multiplication of extracellular parasites within subcutaneous tissues, blood, and the lymphatic system, manifesting clinically with nonspecific constitutional symptoms such as intermittent fever, lymphadenopathy, cephalalgia, and arthralgia. The second, or meningoencephalitic stage, occurs when trypanosomes cross the blood-brain barrier into the central nervous system, eliciting widespread neuroinflammation, neuropsychiatric disturbances, severe circadian rhythm disintegration—yielding the classical hallmark of daytime somnolence and nocturnal insomnia—and terminal encephalopathy.
2. Etymology & Linguistic Origin
The generic name Trypanosoma is derived from classical Greek roots: the noun trypanon (τρύπανον), signifying an “auger,” “borer,” or “drill,” combined with soma (σῶμα), meaning “body.” This morphological designation was coined in 1843 by the French physician and naturalist David Gruby to describe the corkscrew-like, undulating motility demonstrated by the extracellular protozoans when observed under light microscopy. The specific epithet brucei commemorates Major-General Sir David Bruce, the Scottish microbiologist and naval pathologist who established the link between trypanosomes, tsetse flies, and the livestock disease nagana in 1895, and subsequently contributed to elucidating the vector of human infection.
The geographic qualifiers gambiense and rhodesiense correspond to the colonial administrative territories from which representative pathological specimens were first isolated and characterized: the Gambia River basin in West Africa and the historical region of Rhodesia (modern-day Zambia and Zimbabwe) in Southern Africa, respectively. The popular moniker “sleeping sickness” arose during the eighteenth and nineteenth centuries as European colonial medical officers documented the profound somnolence, apathy, and terminal catatonic stupor exhibited by indigenous populations suffering from advanced neurological manifestations of the disease.
3. Pronunciation & Grammatical Form
In standard medical English, African trypanosomiasis is pronounced /ˌæf.rɪ.kən ˌtrɪp.əˌnoʊ.səˈmaɪ.ə.sɪs/ (US) or /ˌæf.rɪ.kən ˌtrɪp.æ.nəʊ.saɪˈeɪ.sɪs/ (UK). The taxonomic genus is pronounced /ˌtrɪp.ə.noʊˈsoʊ.mə/.
Grammatically, “trypanosomiasis” operates as an uncountable abstract noun denoting a pathological condition. The plural form, seldom used outside comparative taxonomic contexts, is “trypanosomiases” (/ˌtrɪp.əˌnoʊ.səˈmaɪ.ə.siːz/). Derived morphological variants include the noun “trypanosome” (the causative organism), the adjective “trypanosomal” (pertaining to the parasite or the infection), and the descriptive adjective “trypanocidal” (substances capable of killing the parasite). In clinical and global public health discourse, the acronym “HAT” (Human African Trypanosomiasis) is universally utilized as an abbreviated nominal construct.
4. Detailed Conceptual Explanation
Human African Trypanosomiasis constitutes one of humanity’s most complex host-pathogen evolutionary conflicts. The etiology relies strictly on vector-host transmission cycles sustained by tsetse flies of the genus Glossina, which are confined entirely to sub-Saharan Africa between latitudes 14° North and 20° South, a bioclimatic region historically designated as the “tsetse fly belt.” Both male and female tsetse flies are obligate blood feeders, meaning that transmission can occur regardless of the vector’s sex when an infected insect inoculates metacyclic trypomastigotes into the mammalian dermis during a blood meal.
Following dermal inoculation, the parasites rapidly transform into bloodstream trypomastigotes and proliferate by longitudinal binary fission within the interstitial connective tissue, often producing a localized inflammatory induration known as a trypanosomal chancre. From the skin, the parasites invade regional lymph nodes and enter the bloodstream, initiating Stage 1 (the hemolymphatic stage). A distinctive biological attribute of Trypanosoma brucei is its strictly extracellular lifecycle within the mammalian host; unlike Trypanosoma cruzi (the intracellular agent of Chagas disease) or Leishmania species, African trypanosomes never enter host cells, remaining continually exposed to humoral immune surveillance.
The survival of the parasite in the face of continuous host antibody production is mediated by antigenic variation—a sophisticated molecular mechanism wherein the trypanosome periodically sheds and alters its dense, outer variant surface glycoprotein (VSG) coat. By the time the host develops high-titer neutralizing antibodies against a dominant VSG homodimer, a small subpopulation of the parasite population has transcribed a distinct VSG gene from its repertoire of over a thousand silent genes and pseudogenes. This cyclic antigenic evasion creates alternating waves of parasitemia, clinical remission, and symptomatic relapse, systematically exhausting the host immune system.
As the chronic immune activation persists, the parasites penetrate the vascular endothelium of the blood-brain barrier and blood-cerebrospinal fluid barrier, establishing Stage 2 (the meningoencephalitic stage). Once established within the central nervous system, trypanosomes trigger astrogliosis, microglial activation, and an extensive perivascular lymphocytic infiltration known as cuffing. The resulting neuroinflammation affects the hypothalamus, thalamus, and basal ganglia, inducing severe disruptions of endocrine function and the suprachiasmatic nucleus—the master circadian clock of the brain. The clinical picture shifts from constitutional debility to progressive cognitive impairment, sensory disturbances, motor deficits, dysarthria, extreme cachexia, and irreversible neurological deterioration.
5. Historical Development
The historical trajectory of African trypanosomiasis is deeply intertwined with the social, political, and ecological history of the African continent. Indigenous populations long recognized the correlation between certain fly-dense riverine woodlands and deadly wasting diseases in cattle and humans. Early written descriptions in the Western record date back to the fourteenth-century Arab geographer Ibn Battuta, who observed clinical sleep lethargy in the Kingdom of Mali, and the eighteenth-century British naval surgeon John Atkins, who described the “sleeping distemper” among enslaved West Africans in his 1734 treatise.
During the late nineteenth and early twentieth centuries, the social upheavals of European colonial expansion—characterized by forced labor migrations, military movements, and the disruption of traditional land management—precipitated catastrophic epidemics. Between 1896 and 1906, an enormous sleeping sickness epidemic decimated the Congo Basin and the northern shores of Lake Victoria in Uganda, killing an estimated 300,000 to 500,000 people. This human disaster prompted major colonial powers to establish tropical disease commissions.
Scientific identification of the pathogen accelerated rapidly between 1895 and 1910. Sir David Bruce demonstrated that the livestock disease nagana was caused by a protozoan transmitted by tsetse flies in Zululand in 1895. In 1901, British physician Robert Michael Forde and colonial surgeon Joseph Everett Dutton isolated trypanosomes from the blood of a patient in the Gambia, with Dutton proposing the name Trypanosoma brucei gambiense in 1902. Simultaneously, Aldo Castellani recovered trypanosomes from the cerebrospinal fluid of sleeping sickness patients in Uganda, confirming the neurological link. In 1910, John William Watson Stephens and Harold Benjamin Fantham differentiated the more virulent, zoonotic eastern variant, naming it Trypanosoma brucei rhodesiense.
Mid-twentieth-century control strategies, pioneered by figures like the French military physician Eugène Jamot, relied on mobile screening teams conducting systematic population censuses, manual palpation of cervical lymph nodes, and microscopic examination. These public health efforts brought the disease near the brink of elimination by the early 1960s. However, following decolonization, civil conflicts and collapsing surveillance systems sparked major resurgences in the 1980s and 1990s, particularly in Angola, the Democratic Republic of the Congo, and southern Sudan. Renewed multinational public-private partnerships orchestrated by the World Health Organization (WHO) have since driven global incidence down to historic lows, shifting the paradigm from epidemic containment to targeted elimination.
6. Theoretical Foundations & Pathophysiological Models
The pathophysiology of African trypanosomiasis represents a paradigm of molecular evasion, immunopathology, and neurovascular interface degradation. Modern biomedical frameworks explain the progression through three interdependent models: the antigenic variation paradigm, the inflammatory cytokine cascade model, and the neuroimmune sleep-regulation model.
At the molecular core of the disease is the antigenic variation paradigm. The trypanosome surface is covered by approximately 10 million molecules of a single Variant Surface Glycoprotein (VSG), forming an impenetrable physical barrier that conceals invariant transmembrane proteins from host immunoglobulins. Expression of a VSG is monoallelic and occurs from dedicated telomeric Expression Sites (ES). Switching occurs via homologous recombination, gene conversion, or transcriptional switching between distinct expression sites. This mechanism prevents sterilizing immunity; the host cannot clear the infection despite generating colossal quantities of non-specific and specific immunoglobulin M (IgM), producing the profound hypergammaglobulinemia characteristic of the disease.
The systemic pathology is fundamentally immunopathogenic rather than toxin-mediated. The persistent phagocytosis of trypanosomal debris by the reticuloendothelial system induces massive macrophage activation, triggering unregulated secretion of pro-inflammatory cytokines, specifically Tumor Necrosis Factor-alpha (TNF-α), Interleukin-1 (IL-1), Interleukin-6 (IL-6), and interferon-gamma (IFN-γ). TNF-α, originally designated as “cachectin,” mediates the profound muscle wasting, high fevers, and hemolytic anemia observed in infected hosts. Circulating immune complexes of VSG antigens and IgM deposit within vascular basements, resulting in generalized vasculitis, splenomegaly, glomerulonephritis, and microcirculatory compromise.
The central nervous system pathology is elucidated through the neuroimmune breakdown model. Entry across the blood-brain barrier occurs primarily via transcytosis across cerebral endothelial cells without disrupting structural junctional proteins in early CNS involvement. Once the parasite enters the parenchyma and the perivascular Virchow-Robin spaces, microglial cells and astrocytes react by secreting nitric oxide, prostaglandins (particularly Prostaglandin D2, a potent endogenous somnogen), and matrix metalloproteinases. This continuous localized neuroinflammation disrupts the neural circuitry of the ascending reticular activating system and the preoptic anterior hypothalamus, producing the pathognomonic fragmentation of sleep architecture, wherein rapid eye movement (REM) sleep intrudes abnormally into daytime hours.
7. Key Components, Types & Dimensions
African trypanosomiasis manifests across distinct biological taxa, epidemiological cycles, and clinical disease phases:
- Trypanosoma brucei gambiense (Western/Central African HAT): Represents more than 95% of all reported human cases. It causes an anthroponotic, slow-progressing, chronic clinical course. Humans act as the primary epidemiological reservoir, although domestic animals (such as pigs and dogs) can harbor the parasite. The disease may remain in the hemolymphatic phase for months or years before penetrating the central nervous system.
- Trypanosoma brucei rhodesiense (Eastern/Southern African HAT): Represents fewer than 5% of reported cases. It causes a virulent, zoonotic, acute clinical syndrome. Wild ungulates (e.g., bushbucks, waterbucks, lions) and domestic livestock (specifically cattle) serve as the primary animal reservoir, with humans acting as accidental dead-end hosts. Neurological invasion typically occurs within weeks of the initial bite, often leading to rapid cardiac involvement and death within months if unmanaged.
- Animal African Trypanosomiasis (Nagana): Caused primarily by related taxa including Trypanosoma congolense, Trypanosoma vivax, and Trypanosoma brucei brucei. This condition limits agricultural productivity across sub-Saharan Africa by inducing lethal anemia and wasting in cattle, horses, and small ruminants. Humans are naturally immune to T. b. brucei due to the presence of serum trypanolytic factors (Apolipoprotein L1 and Haptoglobin-Related Protein).
- Stage 1: Hemolymphatic Stage: Characterized by parasite proliferation strictly outside the blood-brain barrier. Hallmark features include intermittent pyrexia, pruritus, hepatosplenomegaly, and non-tender cervical lymph node enlargement, classically known as Winterbottom’s sign.
- Stage 2: Meningoencephalitic Stage: Defined by neuroinvasion of the cerebral parenchyma and cerebrospinal fluid. Characterized by sleep architecture disruption, pyramidal and extrapyramidal motor deficits (tremors, ataxia, chorea), sensory hyperesthesia (Kerandel’s sign), severe mood shifts, hallucinations, catatonia, and eventual coma.
8. Examples & Illustrative Cases
To conceptualize the stark divergence between the two forms of the disease, clinical vignettes illustrate their disparate clinical presentations and timelines:
Case 1: Chronic Gambiense Infection in an Agrarian Setting. A 34-year-old female farmer living in the Mai-Ndombe province of the Democratic Republic of the Congo presented to a rural health post with an eighteen-month history of intermittent fevers, recurrent headaches, and profound weight loss. Her family reported progressive personality changes over the preceding five months, including unprovoked aggression, visual hallucinations, and daytime somnolence that prevented her from farming. Physical examination revealed posterior cervical lymphadenopathy (Winterbottom’s sign) and mild postural hand tremor. Serological screening via the Card Agglutination Test for Trypanosomiasis (CATT) was strongly positive. A diagnostic lumbar puncture revealed an elevated white blood cell count of 85 cells/μL in the cerebrospinal fluid, along with motile trypomastigotes visible under light microscopy. This confirmed Stage 2 T. b. gambiense infection. She was successfully treated with an all-oral course of fexinidazole, yielding complete clinical remission over six months.
Case 2: Acute Rhodesiense Infection in a Wildlife Warden. A 28-year-old park ranger stationed in the Luangwa Valley of Zambia developed a painful, indurated erythematous lesion on his lower leg twelve days after receiving multiple painful bites from tsetse flies during an anti-poaching patrol. Within 72 hours of the lesion’s appearance, he developed high spiking fevers (40°C), severe myalgia, jaundice, and tachycardia. Initial malaria smears were negative. By day six of symptom onset, he became acutely delirious with signs of myocarditis and acute kidney injury. A peripheral Giemsa-stained blood smear revealed high concentrations of extracellular flagellated trypomastigotes. Cerebrospinal fluid analysis revealed elevated protein and trypanosomes within three weeks of initial exposure. He was diagnosed with acute Stage 2 T. b. rhodesiense infection and urgently treated with intravenous suramin followed by melarsoprol, surviving with residual peripheral neuropathy.
9. Measurement & Diagnostic Assessment
The diagnostic pathway for African trypanosomiasis is a rigorous multi-tier process comprising serological screening, parasitological confirmation, and disease staging to guide appropriate pharmacotherapy.
Screening for T. b. gambiense relies heavily on the Card Agglutination Test for Trypanosomiasis (CATT), a rapid, field-adapted serological assay that detects circulating antibodies against the predominant LiTat 1.3 VSG antigen. In recent years, lateral-flow Rapid Diagnostic Tests (RDTs) employing recombinant antigens have supplemented or replaced CATT in decentralized rural clinics. For T. b. rhodesiense, no reliable serological screening test exists; high parasitemia mandates direct parasitological assessment.
Microscopic confirmation requires direct visualization of motile or stained parasites. Diagnostic specimens include fluid aspirated from enlarged lymph nodes, wet blood preparations, thick blood films, or Giemsa-stained thin smears. Because parasitemia in T. b. gambiense can be extraordinarily low (frequently fewer than 100 parasites/mL), specialized concentration techniques are often required. These include the capillary tube centrifugation technique (Woo test), the miniature anion-exchange centrifugation technique (mAECT), and quantitative buffy coat (QBC) analysis.
Staging the disease historically determined whether highly toxic neurotropic drugs had to be administered. Staging requires a lumbar puncture to examine the cerebrospinal fluid (CSF). The WHO criteria define Stage 2 disease by either the presence of trypanosomes in the CSF (detected via modified double centrifugation) or a CSF white blood cell count exceeding 5 cells/μL. A leukocyte count of 0–5 cells/μL indicates Stage 1. Molecular methods such as polymerase chain reaction (PCR) and loop-mediated isothermal amplification (LAMP) provide exquisite analytical sensitivity, but their utility remains primarily translational and academic rather than standard field practice.
10. Applications & Practical Significance
The management and control of African trypanosomiasis represent an intersection of clinical pharmacology, vector biology, and public health infrastructure. Therapeutics for HAT have historically presented severe clinical challenges due to their toxicity, age, and complex parenteral administration routes.
Pharmacological intervention is stratified by parasite subspecies and clinical stage:
- Pentamidine: An aromatic diamidine utilized as the first-line therapy for Stage 1 T. b. gambiense. It does not cross the blood-brain barrier effectively and is administered intramuscularly for 7–10 days. Common adverse reactions include hypotension, hypoglycemia, and injection-site pain.
- Suramin: A polysulfonated naphthylamine used primarily for Stage 1 T. b. rhodesiense. It requires intravenous infusion and carries risks of nephrotoxicity, photophobia, and peripheral neuropathy.
- Melarsoprol: An organoarsenic compound introduced in 1949 that crosses the blood-brain barrier. Historically the sole therapy for Stage 2 of both forms, it remains the only available regimen for Stage 2 T. b. rhodesiense. Melarsoprol is notoriously toxic; it is dissolved in propylene glycol and induces a lethal reactive encephalopathic syndrome (post-treatment reactive encephalopathy, PTRE) in up to 10% of treated patients, with a 50% fatality rate among those who develop it.
- NECT (Nifurtimox-Eflornithine Combination Therapy): Implemented in 2009 as the standard first-line treatment for Stage 2 T. b. gambiense. This co-administration of oral nifurtimox and intravenous eflornithine (an irreversible inhibitor of ornithine decarboxylase) reduced treatment duration and lowered drug-induced mortality to under 1%, phasing out melarsoprol for Gambian sleeping sickness.
- Fexinidazole: Approved in 2018 by the European Medicines Agency under Article 58, fexinidazole is an oral 2-substituted 5-nitroimidazole derivative that revolutionized T. b. gambiense therapy. Taken once daily with food for 10 days, it is active against both Stage 1 and non-advanced Stage 2 disease, eliminating the absolute necessity of lumbar punctures for staging before initiating therapy. In 2023, the indication expanded to include T. b. rhodesiense treatment.
Beyond clinical case management, practical vector control remains crucial. Tsetse populations are suppressed through the deployment of insecticide-impregnated blue-black fabric targets and biconical traps, which exploit the flies’ visual attraction to blue hues and dark contrasts. Micro-target grids, livestock insecticide dipping, and the release of sterile male insect techniques (SIT) have historically driven successful local elimination, such as the total eradication of Glossina austeni from Unguja Island in Zanzibar.
11. Research & Empirical Evidence
Contemporary clinical research has centered on discovering non-toxic, oral, single-dose therapies capable of curing all stages of human trypanosomiasis. A landmark study conducted by the Drugs for Neglected Diseases initiative (DNDi) and published in The Lancet (Mesuvire et al., 2018) established the non-inferiority of oral fexinidazole compared to standard NECT in Stage 2 T. b. gambiense, demonstrating a cure rate exceeding 91% at 18 months follow-up.
Following this milestone, investigation shifted toward acoziborole (SCYX-7158), a novel benzoxaborole derivative that inhibits parasite cleavage and polyadenylation specificity factor subunit 3 (CPSF3). In a multicenter, prospective open-label trial across the Democratic Republic of the Congo and Guinea (Kande et al., 2023, published in The Lancet Infectious Diseases), a single oral dose of 960 mg acoziborole demonstrated an efficacy of 95.2% in patients with Stage 2 HAT at 18 months, accompanied by a favorable safety profile. The advent of an effective single-dose oral cure removes the logistical obstacles associated with prolonged hospital stays and repeated intravenous infusions in conflict-affected regions.
Epidemiologically, empirical surveys compiled by the WHO indicate a dramatic reduction in disease burden. In 1999, nearly 40,000 cases were reported globally, with an estimated 300,000 undiagnosed cases. By 2020, annual reported cases dropped below 1,000 for the first time in documented history, and by 2022, only 837 cases were registered across the continent. These empirical benchmarks validate the WHO Neglected Tropical Diseases Roadmap goals: achieving the elimination of T. b. gambiense as a public health problem by 2020, and achieving complete interruption of transmission by 2030.
12. Cultural & Cross-Cultural Considerations
The manifestation of neurological symptoms in sleeping sickness intersects profoundly with local indigenous belief systems, mental health stigma, and rural social structures. Because Stage 2 sleeping sickness triggers complex psychiatric phenomena—including sudden aggression, emotional lability, mutism, inappropriate laughter, and somnambulism—affected individuals have historically been perceived by their communities as experiencing spiritual possession, ancestral punishment, or intentional witchcraft.
This cultural attribution often diverts symptomatic individuals away from biomedical clinics and toward traditional healers, faith-based sanctuaries, or complete social isolation. Delayed clinical presentation worsens the prognosis and increases the risk of household impoverishment. The lethargy and cognitive decline associated with HAT also incur severe socioeconomic costs on rural families. The inability of primary food producers to work leads to chronic malnutrition, school absenteeism among children who must assume adult labor, and community impoverishment.
From an ecological and agricultural perspective, the “tsetse fly belt” has historically dictated the human geography of sub-Saharan Africa. The presence of nagana prevented the sustained use of draft animals (such as oxen and horses) for agricultural plowing and transport throughout tropical Africa for millennia. Anthropologists and economic historians observe that this vector-enforced limitation restricted heavy tillage, reduced agricultural surpluses, hindered urbanization, and profoundly influenced pre-colonial societal development.
13. Criticisms, Debates & Limitations
Despite unprecedented epidemiological success, several critical controversies, ethical debates, and technical challenges persist regarding the endgame of African trypanosomiasis elimination.
A primary debate concerns the existence and significance of cryptic animal and asymptomatic human reservoirs. While T. b. gambiense was traditionally regarded as an exclusively human infection, extensive molecular surveillance has detected the parasite in domestic pigs, sheep, goats, and wild fauna. Some researchers argue that as active human-to-human transmission drops toward zero, these animal reservoirs—along with asymptomatic human “silent carriers” who maintain low-level parasitemia without clinical progression—could sustain parasite circulation and ignite sudden resurgences if vertical surveillance programs are dismantled.
Another debate centers on the allocation of global health resources. As annual case counts drop to fewer than a thousand across the entire continent, the cost per detected case rises exponentially. Critics question whether sustaining dedicated, disease-specific mobile surveillance units is cost-effective compared to integrating screening into broad primary healthcare networks. Conversely, advocates argue that premature integration caused the disastrous epidemics of the 1980s and 1990s, warning that without active targeted screening in remote hotspots, the final pockets of transmission will escape detection.
Finally, ethical debates have emerged over clinical trials conducted in vulnerable rural African populations during active civil conflicts, particularly concerning historical reliance on melarsoprol. Given the drug’s high iatrogenic mortality (5% of all treated individuals dying from arsenic-induced encephalopathy), bioethicists have scrutinized the prolonged delay between the recognition of melarsoprol’s toxicity and the modern development of less toxic alternatives like NECT, fexinidazole, and acoziborole.
14. Related Terms & Distinctions
Clarifying the boundaries between African trypanosomiasis and related clinical or parasitological entities is critical for accurate nosology and differential diagnosis:
- American Trypanosomiasis (Chagas Disease): Caused by Trypanosoma cruzi and transmitted by triatomine bugs (“kissing bugs”) in the Americas. Unlike African trypanosomiasis, T. cruzi is primarily an intracellular parasite, does not undergo VSG antigenic variation, and affects the cardiovascular and gastrointestinal systems (causing cardiomyopathy and megaviscera) rather than the central nervous system sleep architecture.
- Nagana (Animal African Trypanosomiasis): Caused by Trypanosoma congolense, T. vivax, and T. brucei brucei in domestic livestock. It produces severe wasting, anemia, and abortion in animals but is non-pathogenic in healthy humans due to innate human trypanolytic factors.
- Visceral Leishmaniasis (Kala-Azar): A protozoan infection caused by Leishmania donovani or Leishmania infantum, transmitted by phlebotomine sandflies. While it shares overlapping systemic manifestations with Stage 1 HAT—such as prolonged fever, cachexia, and splenomegaly—it is strictly intracellular (infecting macrophages) and diagnosed via bone marrow or splenic aspirates.
- Cerebral Malaria: A severe neurological complication of Plasmodium falciparum infection characterized by intraerythrocytic sequestration, unarousable coma, and acute encephalopathy. Cerebral malaria exhibits an acute onset over hours or days, unlike the subacute or chronic progression observed in Stage 2 HAT.
15. Summary & Key Takeaways
African trypanosomiasis remains an iconic model of evolutionary parasitology, vector-borne disease dynamics, and the challenges of neglected disease elimination in tropical regions. Key conceptual and clinical takeaways include:
- The disease is caused by protozoan parasites of the Trypanosoma brucei complex and transmitted solely by tsetse flies of the genus Glossina in sub-Saharan Africa.
- It exists as two distinct epidemiological entities: chronic West and Central African sleeping sickness (caused by T. b. gambiense, accounting for >95% of cases) and acute East and Southern African sleeping sickness (caused by T. b. rhodesiense, a virulent zoonosis).
- Its extracellular survival in the mammalian host is facilitated by variant surface glycoprotein (VSG) antigenic variation, which periodically exhausts and evades the host immune response.
- The disease progresses from an initial hemolymphatic phase (fever, lymphadenopathy, organomegaly) to a meningoencephalitic stage (blood-brain barrier penetration, profound circadian sleep disruptions, neuropsychiatric collapse, and coma).
- Therapeutics have evolved from toxic, arsenic-based regimens (melarsoprol) toward combination protocols (NECT) and revolutionary all-oral, single-dose therapies (fexinidazole and acoziborole).
- Global public health efforts have reduced annual caseloads by more than 98% over the past two decades, transforming this ancient fatal condition into a model for targeted neglected tropical disease elimination.
References
- Büscher, P., Cecchi, G., Jamonneau, V., & Priotto, G. (2017). Human African trypanosomiasis. The Lancet, 390(10110), 2397–2409. https://doi.org/10.1016/S0140-6736(17)31510-6
- Franco, J. R., Cecchi, G., Priotto, G., Paone, M., Diarra, A., Grout, L., Simarro, P. P., Zhao, W., & Argaw, D. (2022). Monitoring the elimination of human African trypanosomiasis at continental and country level: Update to 2020. PLOS Neglected Tropical Diseases, 16(5), e0010418. https://doi.org/10.1371/journal.pntd.0010418
- Kande, V. N., Mutombo, W., Valverde Mordt, O., Scherrer, B., Ilunga, M., Mutanda, S., Scholfield, D., & Strub-Wourgaft, N. (2023). Safety and efficacy of acoziborole in patients with human African trypanosomiasis: An open-label, multicentre, prospective, phase 2/3 study. The Lancet Infectious Diseases, 23(4), 463–470. https://doi.org/10.1016/S1473-3099(22)00660-0
- Mesu, V. K. B. K., Kalonji, W. M., Bardonneau, C., Valverde Mordt, O., Blesson, S., Simon, F., Delhomme, S., Bernhard, S., Kuziena, W., Fina Lubaki, J. P., & Tarral, A. (2018). Oral fexinidazole for late-stage African Trypanosoma brucei gambiense trypanosomiasis: A pivotal multicentre, randomised, non-inferiority trial. The Lancet, 391(10116), 144–154. https://doi.org/10.1016/S0140-6736(17)32758-7
- World Health Organization. (2020). Ending the neglect to attain the Sustainable Development Goals: A road map for neglected tropical diseases 2021–2030. World Health Organization. https://www.who.int/publications/i/item/9789240010352